Compare CRL & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | KYMR |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.8B |
| IPO Year | 1999 | 2020 |
| Metric | CRL | KYMR |
|---|---|---|
| Price | $159.98 | $78.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 26 |
| Target Price | ★ $200.09 | $107.72 |
| AVG Volume (30 Days) | ★ 733.7K | 585.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,857,601,000.00 | $39,211,000.00 |
| Revenue This Year | $0.99 | $11.85 |
| Revenue Next Year | $3.26 | $7.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $91.86 | $19.45 |
| 52 Week High | $228.88 | $103.00 |
| Indicator | CRL | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 46.67 |
| Support Level | $158.36 | $77.78 |
| Resistance Level | $166.62 | $95.90 |
| Average True Range (ATR) | 6.77 | 3.77 |
| MACD | 1.36 | -0.31 |
| Stochastic Oscillator | 52.98 | 50.67 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.